However, the signature generalized well in that (a) it was highly correlated with 2 other IL-17 gene signatures (a signature previously studied in asthma [ref. 39] and a signature fit to SLC26A4, the most significantly upregulated gene in our IL-17–stimulated human bronchial epithelial culture experiments) and (b) our IL-17 signature was responsive to anti–IL-17 therapy and reflective of clinical response in 2 randomized controlled trials in psoriasis. The gene discussed is SLC26A4; the disease is psoriasis.